Akebia Therapeutics expands stock incentive plan
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Akebia Ther (AKBA)
Akebia Ther stock price live, this page displays NASDAQ AKBA stock exchange data. View the AKBA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Akebia Ther real time stock price chart below.
What Is the Akebia Ther Stock Price Today?
The Akebia Ther stock price today is 3.980.
What Is the Stock Symbol for Akebia Ther?
The stock symbol for Akebia Ther is ""AKBA.""
What Stock Exchange Does Akebia Ther Trade On?
Akebia Ther is listed and trades on the NASDAQ stock exchange.
Is Akebia Ther a Good Stock to Buy?
Determining whether Akebia Ther—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKBA quote. (ISIN: US00972D1054)
What Is the Akebia Ther Stock Price Today?
The Akebia Ther stock price today is 3.980.
What Is the Stock Symbol for Akebia Ther?
The stock symbol for Akebia Ther is ""AKBA.""
What Stock Exchange Does Akebia Ther Trade On?
Akebia Ther is listed and trades on the NASDAQ stock exchange.
Is Akebia Ther a Good Stock to Buy?
Determining whether Akebia Ther—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AKBA quote. (ISIN: US00972D1054)
NASDAQ
Currency in USD
3.980
+0.270(+7.28%)
Closed·
After Hours
4.049+0.059(+1.49%)
·
Fair Value
An estimate of a Akebia Ther's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.720
4.010
52 wk Range
0.985
4.076
AKBA Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
AKBA is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Akebia Ther's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.7204.010
52 wk Range
0.9854.076
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AKBA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Akebia Ther's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
7.400
Upside
+85.93%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
- Form 8K Akebia Ther For: 13 June
- Investing.com
- Akebia Therapeutics expands stock incentive plan
- Investing.com
- Form 8K Akebia Ther For: 13 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Akebia Ther Company Profile
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Akebia Ther Earnings Call Summary for Q1/2025
- Akebia Therapeutics beats Q1 2025 estimates with EPS of $0.03 vs -$0.05 forecast; revenues rise to $57.3M, surpassing $44.38M projection
- Stock surges 15.49% in premarket trading to $2.841, nearing 52-week high; company valued at $644M with 76% return over past year
- Net income turns positive at $6.1M from $18M loss; strong sales of Vafcio and Auryxia drive growth; cash position at $113.4M
- Phase III VALOR trial planned for H2 2025; company vigilant about potential Auryxia generic competition
- Analysts project -$0.15 EPS for FY2025; price targets range from $6 to $10 despite current slight overvaluation
Last Updated: 08/05/2025, 13:52
Read Full TranscriptCompare AKBA to Peers and Sector
Metrics to compare | AKBA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAKBAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.4x | −1.5x | −0.5x | |
PEG Ratio | −2.61 | −0.01 | 0.00 | |
Price/Book | 39.5x | 0.7x | 2.6x | |
Price / LTM Sales | 5.3x | 8.1x | 3.1x | |
Upside (Analyst Target) | 88.7% | 145.1% | 47.8% | |
Fair Value Upside | Unlock | 15.9% | 6.9% | Unlock |
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.400
(+85.93% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
0.03 / -0.05
Revenue / Forecast
57.34M / 44.38M
People Also Watch
FAQ
What Stock Exchange Does Akebia Ther Trade On?
Akebia Ther is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Akebia Ther?
The stock symbol for Akebia Ther is "AKBA."
What Is the Akebia Ther Market Cap?
As of today, Akebia Ther market cap is 1.04B.
What Is Akebia Ther's Earnings Per Share (TTM)?
The Akebia Ther EPS (TTM) is -0.21.
When Is the Next Akebia Ther Earnings Date?
Akebia Ther will release its next earnings report on 30 Jul 2025.
From a Technical Analysis Perspective, Is AKBA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Akebia Ther Stock Split?
Akebia Ther has split 0 times.
How Many Employees Does Akebia Ther Have?
Akebia Ther has 181 employees.
What is the current trading status of Akebia Ther (AKBA)?
As of 09 Jul 2025, Akebia Ther (AKBA) is trading at a price of 3.98, with a previous close of 3.71. The stock has fluctuated within a day range of 3.72 to 4.01, while its 52-week range spans from 0.99 to 4.08.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.